This company listing is no longer active
MR4 Stock Overview
Meridian Bioscience, Inc., a life science company, develops, manufactures, distributes, and sells diagnostic test kits primarily for gastrointestinal and respiratory infectious diseases, and elevated blood lead levels worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 1/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Meridian Bioscience, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$30.90 |
| 52 Week High | US$33.18 |
| 52 Week Low | US$18.52 |
| Beta | 0.23 |
| 1 Month Change | 0.26% |
| 3 Month Change | -5.99% |
| 1 Year Change | 63.75% |
| 3 Year Change | 312.00% |
| 5 Year Change | 160.98% |
| Change since IPO | 1,254.40% |
Recent News & Updates
Recent updates
Shareholder Returns
| MR4 | DE Medical Equipment | DE Market | |
|---|---|---|---|
| 7D | 0.9% | 0.2% | -0.5% |
| 1Y | 63.8% | -11.2% | 15.5% |
Return vs Industry: MR4 exceeded the German Medical Equipment industry which returned -15.8% over the past year.
Return vs Market: MR4 exceeded the German Market which returned -11.9% over the past year.
Price Volatility
| MR4 volatility | |
|---|---|
| MR4 Average Weekly Movement | 2.3% |
| Medical Equipment Industry Average Movement | 5.5% |
| Market Average Movement | 5.3% |
| 10% most volatile stocks in DE Market | 12.0% |
| 10% least volatile stocks in DE Market | 2.8% |
Stable Share Price: MR4 has not had significant price volatility in the past 3 months.
Volatility Over Time: MR4's weekly volatility (2%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1976 | 704 | Jack Kenny | www.meridianbioscience.com |
Meridian Bioscience, Inc., a life science company, develops, manufactures, distributes, and sells diagnostic test kits primarily for gastrointestinal and respiratory infectious diseases, and elevated blood lead levels worldwide. The company operates through Diagnostics and Life Science segments. The Diagnostics segment offers testing platforms, including real-time PCR amplification under the Revogene brand; isothermal DNA amplification under the Alethia brand; lateral flow immunoassay using fluorescent chemistry under the Curian brand; rapid immunoassay under the ImmunoCard and ImmunoCard STAT!
Meridian Bioscience, Inc. Fundamentals Summary
| MR4 fundamental statistics | |
|---|---|
| Market cap | €1.38b |
| Earnings (TTM) | €39.06m |
| Revenue (TTM) | €306.34m |
35.2x
P/E Ratio4.5x
P/S RatioIs MR4 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MR4 income statement (TTM) | |
|---|---|
| Revenue | US$333.02m |
| Cost of Revenue | US$144.66m |
| Gross Profit | US$188.36m |
| Other Expenses | US$145.90m |
| Earnings | US$42.46m |
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.96 |
| Gross Margin | 56.56% |
| Net Profit Margin | 12.75% |
| Debt/Equity Ratio | 6.8% |
How did MR4 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2023/02/01 04:48 |
| End of Day Share Price | 2023/01/30 00:00 |
| Earnings | 2022/09/30 |
| Annual Earnings | 2022/09/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Meridian Bioscience, Inc. is covered by 15 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Catherine Ramsey Schulte | Baird |
| Mark Massaro | Canaccord Genuity |
| Zarak Khurshid | Caris & Company |